Ocular surface applications of Descemet's membrane
后弹力层在眼表的应用
基本信息
- 批准号:10673188
- 负责人:
- 金额:$ 24.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:ABCG2 geneAddressAge related macular degenerationAirAnimal ModelAnteriorAutoimmune DiseasesBasal CellBasement membraneBiologicalBiological AssayBiological MarkersBlindedBlindnessCell TransplantationCellsCharacteristicsChemical BurnsChemical InjuryClinicCollagen Type IVCommunicationCompetenceCorneaDefectDescemet&aposs membraneDevelopmentDigestionDiseaseEffectivenessEngineeringEnvironmentEpithelial CellsExtracellular MatrixExtracellular Matrix ProteinsEye diseasesFutureGoalsHumanImmuneImmunohistochemistryIn VitroLiftingMechanicsMembraneMembrane ProteinsMentored Clinical Scientist Development ProgramMentorsMinnesotaModelingNatural regenerationOperative Surgical ProceduresOpticsOralOrgan Culture TechniquesOutcomePainPatient-Focused OutcomesPatientsPhenotypePhysiologic pulsePhysiologicalPopulationProliferatingProteinsProtocols documentationPublishingQuantitative Reverse Transcriptase PCRRattusRecurrenceRehabilitation therapyReportingResearchResearch PersonnelResistanceResourcesStem cell transplantSurfaceTestingTherapeutic InterventionTimeTissue DonorsTrainingTransplantationUniversitiesVitronectinWorkWritingcell regenerationclinical applicationcollagenasecomparativecomparative efficacyconjunctivacorneal epitheliumcorneal regenerationfetalgraft failureimprovedin vivoinduced pluripotent stem cellinduced pluripotent stem cell technologyinnovationinventionlimbalmeltingmouse modelnovelocular surfacepersonalized medicinepluripotencyprogramsreconstructionregenerative therapyresearch studyskillsstem cell biomarkersstem cell functionstem cellsstemnesssuccesstherapy outcometissue processing
项目摘要
PROJECT SUMMARY/ABSTRACT
Limbal stem cell (LSC) deficiency is a blinding disease that accounts for an estimated 15-20% of corneal
blindness worldwide. LSC deficiency is caused by excessive loss of LSC, a population of pluripotent cells that
regenerate the transparent corneal epithelium. Loss of LSC due to chemical injuries and autoimmune disease
results in corneal conjunctivalization, erosions, and melting. Treatment options are limited; however, cultured
limbal epithelial cell transplantation (CLET) is a promising emerging therapy. In CLET ex vivo expanded limbal
stem/progenitor cells (LSPC) are transplanted onto diseased eyes to replace the native LSC and regenerate the
corneal epithelium. Short-term success has been reported with CLET; however, long-term outcomes have been
limited by loss of transplanted LSPC and recurrence of LSC deficiency over time. One reason for this is the lack
of a supportive niche. Under physiological conditions, the microenvironment of the limbus, known as the limbal
niche, sustains the pluripotency and proliferative potential of native LSC. However, in LSC deficiency, the limbal
niche is often damaged. Identification of synthetic and biological substrates that can function as niche substitutes
to support transplanted LSPC remains an ongoing challenge and an unaddressed barrier to long-term success
in regenerative therapies for the ocular surface. Although human amniotic membrane (HAM) is the primary
substrate used for CLET, it is limited as a long-term niche substitute by its opacity, rapid degradation, and lack
of limbus-specific proteins. In contrast Descemet’s Membrane (DM), is a basement membrane on the posterior
surface of the cornea is clear and resistant to collagenase digestion. Furthermore, the anterior fetal banded layer
of DM is rich in limbus-specific basement membrane proteins, including collagen IV α1, α2 subtypes, vitronectin,
and BM40/SPARC. The goal of this study is to compare the stemness and survival of donor and iPSC-derived
LSPC on DM vs HAM. In aim 1, we will perform in vitro phenotypic and functional comparisons of LSPC cultured
on DM vs HAM using biomarker expression and an organ culture model of LSC deficiency. In aim 2, we will
perform an in vivo comparison of cultured LSPC on DM vs HAM using a mouse model of LSC deficiency. In aim
3, we will compare biomarker expression and capacity to regenerate corneal epithelium in iPSC-derived LSPC
cultured on DM vs HAM. This project has the potential to inform our choice of substrate in CLET and improve
our therapies for LSC deficiency. The training plan will provide the applicant with technical competencies in the
characterization of LSPC, use of animal models of LSC deficiency, and manipulation of iPSC; as well as
professional skills in oral and written communication to facilitate development as an independent investigator.
Training will take place in University of Minnesota’s (UMN) highly collaborative and well-resourced research
environment. The applicant will be mentored by Dr. Deborah Ferrington, a leader in applications of iPSC
technology in age-related macular degeneration, Dr. Ali Djalilian, a pioneer in therapeutic interventions for limbal
stem cell deficiency, and Dr. James Dutton, director of the UMN Stem Cell Institute, Innovation Facilities.
项目概要/摘要
角膜缘干细胞 (LSC) 缺乏症是一种致盲性疾病,约占角膜的 15-20%
全世界失明。 LSC 缺乏是由 LSC 过度丢失引起的,LSC 是一组多能细胞,
再生透明的角膜上皮。由于化学损伤和自身免疫性疾病导致 LSC 丧失
导致角膜结膜化、糜烂和融化。治疗选择有限;然而,有文化的
角膜缘上皮细胞移植(CLET)是一种有前途的新兴疗法。 CLET 离体扩张角膜缘
干/祖细胞(LSPC)被移植到患病的眼睛上以取代天然的LSC并再生
角膜上皮。据报告,CLET 取得了短期成功;然而,长期结果是
随着时间的推移,移植的 LSPC 丢失和 LSC 缺陷复发受到限制。造成这种情况的原因之一是缺乏
一个支持性的利基市场。生理条件下,角膜缘的微环境,称为角膜缘。
利基,维持天然 LSC 的多能性和增殖潜力。然而,在 LSC 缺乏时,角膜缘
利基经常被破坏。鉴定可作为利基替代品的合成和生物底物
支持移植的 LSPC 仍然是一个持续的挑战,也是长期成功的未解决的障碍
眼表再生疗法。虽然人类羊膜 (HAM) 是主要的
用于 CLET 的基质,由于其不透明、快速降解和缺乏,其作为长期利基替代品受到限制。
角膜缘特异性蛋白质。相比之下,后弹力层 (DM) 是后部的基底膜
角膜表面清澈,能抵抗胶原酶消化。此外,胎儿前带层
DM 富含角膜缘特异性基底膜蛋白,包括 IV 型胶原蛋白 α1、α2 亚型、玻连蛋白、
和 BM40/SPARC。本研究的目的是比较供体和 iPSC 来源的干性和存活率
DM vs HAM 的 LSPC。在目标 1 中,我们将对培养的 LSPC 进行体外表型和功能比较
使用生物标志物表达和 LSC 缺陷的器官培养模型对 DM 与 HAM 进行比较。在目标 2 中,我们将
使用 LSC 缺陷小鼠模型对 DM 和 HAM 上培养的 LSPC 进行体内比较。瞄准目标
3,我们将比较 iPSC 衍生的 LSPC 中生物标志物的表达和再生角膜上皮的能力
在 DM 和 HAM 上培养。该项目有可能为我们在 CLET 中选择基材提供信息并改进
我们针对 LSC 缺乏症的疗法。培训计划将为申请人提供以下方面的技术能力
LSPC 的表征、LSC 缺陷动物模型的使用以及 iPSC 的操作;也
口头和书面沟通的专业技能,以促进作为独立调查员的发展。
培训将在明尼苏达大学 (UMN) 高度协作且资源丰富的研究中心进行
环境。申请人将得到iPSC应用领域领军人物Deborah Ferrington博士的指导
年龄相关性黄斑变性技术,角膜缘治疗干预先驱 Ali Djalilian 博士
干细胞缺乏症,以及 UMN 干细胞研究所创新设施主任 James Dutton 博士。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joshua H Hou其他文献
Decellularized Descemet Membrane Anterior Keratoplasty With Allogeneic Simple Limbal Epithelial Transplantation for Partial Limbal Stem Cell Deficiency Following Partial Keratolimbal Allograft Failure.
脱细胞后弹力层前角膜成形术联合同种异体单纯角膜缘上皮移植治疗部分角膜缘同种异体移植失败后部分角膜缘干细胞缺乏。
- DOI:
10.1097/ico.0000000000003565 - 发表时间:
2024 - 期刊:
- 影响因子:2.8
- 作者:
A. Cheung;Cameron B. Reinisch;Joshua H Hou - 通讯作者:
Joshua H Hou
Joshua H Hou的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joshua H Hou', 18)}}的其他基金
Ocular surface applications of Descemet's membrane
后弹力层在眼表的应用
- 批准号:
10448019 - 财政年份:2022
- 资助金额:
$ 24.21万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 24.21万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 24.21万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 24.21万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 24.21万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 24.21万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 24.21万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 24.21万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 24.21万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 24.21万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 24.21万 - 项目类别:
Research Grant